MRNA Soars After Successful COVID-19 Vaccine Study

The equity is up an impressive 486.4% year-over-year

Digital Content Manager
Jul 15, 2020 at 11:05 AM
facebook X logo linkedin

The shares of Moderna Inc (NASDAQ: MRNA) are up 10.4% at $82.83 this morning, earlier hitting a fresh record high of $88.37, after a small-scale study showed its potential COVID-19 vaccine produced high levels of virus-killing antibodies, bolstering hopes the shot could protect against the respiratory disease. No serious side effects were reported in the study, and the biotech firm said it expects to deliver about 500 million doses a year, or possibly up to 1 billion doses per year starting in 2021.

The successful study has lifted MRNA up on the charts. Though shares had recently pulled back and found overhead pressure at the $66 level, support from the 60-day moving average have pushed off any large setbacks. Longer term, the equity is performing well, and sports an impressive 486.4% lead year-over-year.

Analysts were majorly optimistic toward MRNA coming into today, with 11 of the 12 in coverage sporting a "buy" or better rating, and only one carrying a tepid "hold." Meanwhile, the consensus 12-month price target of $96.58 is a whopping 15.3% premium to current levels. Short sellers are building their positions too, however. Short interest is up 25.3% in the last two reporting periods, and the 28.64 million shares sold short make up 9.7% of MRNA's available float.

In the options pits, it looks as if calls are more than tripling puts. In the last 10 days, 68,754 calls were exchanged, as opposed to just 22,398 puts. On the other hand, MRNA's Schaeffer's put/call open interest ratio (SOIR) stands higher than 83% of readings from the past year, implying short-term options traders have been more put-biased than usual.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI